Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer

European Urology

Volumn 65, Issue 2, 2014, Pages 278-286

  Gartrell, Benjamin A ^a   Coleman, Robert E ^b   Fizazi, Karim ^c   Miller, Kurt ^d   Saad, Fred ^e   Sternberg, Cora N ^f   Galsky, Matthew D ^g  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WESTON PARK HOSPITAL   (United Kingdom)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse events; Bisphosphonates; Bone targeted agents; Denosumab; Prostate cancer; Systematic review

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; VITAMIN D; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; DENTAL HEALTH; DRUG TOXICITY; DRUG WITHDRAWAL; FEMUR FRACTURE; FRAGILITY FRACTURE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY FAILURE; KIDNEY FUNCTION; OSTEOCLAST; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

ADVERSE EVENTS; BISPHOSPHONATES; BONE-TARGETED AGENTS; DENOSUMAB; PROSTATE CANCER; SYSTEMATIC REVIEW;

ANDROGEN ANTAGONISTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; HYPOCALCEMIA; IMIDAZOLES; MALE; MOLECULAR TARGETED THERAPY; OSTEOCLASTS; PATIENT SELECTION; PROSTATIC NEOPLASMS; RANK LIGAND; RISK FACTORS; TREATMENT OUTCOME;

EID: 84891837374     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.05.015     Document Type: Review

References (50)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 2010 765 781
3. S.C. Jacobs Spread of prostatic cancer to bone Urology 21 1983 337 344
4. N. Sathiakumar, E. Delzell, and M.A. Morrisey et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006 Prostate Cancer Prostatic Dis 14 2011 177 183
5. S.J. Snedecor, J.A. Carter, S. Kaura, and M.F. Botteman Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis J Med Econ 16 2013 19 29
6. A.M. Lopez, M.A. Pena, and R. Hernandez et al. Fracture risk in patients with prostate cancer on androgen deprivation therapy Osteoporos Int 16 2005 707 711
7. M.J. Rogers, D.J. Watts, and R.G. Russell Overview of bisphosphonates Cancer 80 1997 1652 1660
8. W.J. Boyle, W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 2003 337 342
9. M.R. Smith, J. Eastham, and D.M. Gleason et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 2003 2008 2012
10. M.D. Michaelson, D.S. Kaufman, and H. Lee et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer J Clin Oncol 25 2007 1038 1042
11. Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006;176:972-8; discussion 978.
12. N. Bhoopalam, S.C. Campbell, and T. Moritz et al. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy J Urol 182 2009 2257 2264
13. S.C. Campbell, N. Bhoopalam, and T.E. Moritz et al. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis Urology 75 2010 1138 1143
14. R.S. Israeli, S.J. Rosenberg, and D.R. Saltzstein et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy Clin Genitourin Cancer 5 2007 271 277
15. P. Rodrigues, F.O. Hering, P. Bruna, A. Meller, and Y. Afonso Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy: a prospective open-label controlled study Int J Urol 14 2007 317 320
16. M.R. Smith, B. Egerdie, and N. Hernandez Toriz et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 2009 745 755
17. M.R. Smith, F. Kabbinavar, and F. Saad et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer J Clin Oncol 23 2005 2918 2925
18. M.R. Smith, F. Saad, and R. Coleman et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial Lancet 379 2012 39 46
19. F. Saad, D.M. Gleason, and R. Murray et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
20. K. Fizazi, M. Carducci, and M. Smith et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822
21. T.J. Polascik, R.W. Given, and C. Metzger et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases Urology 66 2005 1054 1059
22. D.P. Dearnaley, M.R. Sydes, and M.D. Mason et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 trial) J Natl Cancer Inst 95 2003 1300 1311
23. E.J. Small, M.R. Smith, J.J. Seaman, S. Petrone, and M.O. Kowalski Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer J Clin Oncol 21 2003 4277 4284
24. K.P. Weinfurt, K.J. Anstrom, L.D. Castel, K.A. Schulman, and F. Saad Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer Ann Oncol 17 2006 986 989
25. R.E. Marx Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J Oral Maxillofac Surg 61 2003 1115 1117
26. Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009;182:509-15; discussion 515-6.
27. K. Fizazi, A. Lipton, and X. Mariette et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates J Clin Oncol 27 2009 1564 1571
28. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76.
29. A.O. Hoff, B.B. Toth, and K. Altundag et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates J Bone Miner Res 23 2008 826 836
30. K. Vahtsevanos, A. Kyrgidis, and E. Verrou et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw J Clin Oncol 27 2009 5356 5362
31. A. Bamias, E. Kastritis, and C. Bamia et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J Clin Oncol 23 2005 8580 8587
32. C. Walter, B. Al-Nawas, and K.A. Grötz et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate Eur Urol 54 2008 1066 1072
33. F. Saad, J.E. Brown, and C. Van Poznak et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases Ann Oncol 23 2012 1341 1347
34. J.V. Bagan, Y. Jimenez, and J. Murillo et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions: study of 20 cases Oral Oncol 42 2006 327 329
35. T. Mavrokokki, A. Cheng, B. Stein, and A. Goss Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia J Oral Maxillofac Surg 65 2007 415 423
36. R.E. Marx, Y. Sawatari, M. Fortin, and V. Broumand Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment J Oral Maxillofac Surg 63 2005 1567 1575
37. J.B. Aragon-Ching, Y.M. Ning, and C.C. Chen et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents Cancer Inves 27 2009 221 226
38. F. Jadu, L. Lee, M. Pharoah, D. Reece, and L. Wang A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients Ann Oncol 18 2007 2015 2019
39. J.H. Wessel, T.B. Dodson, and A.I. Zavras Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study J Oral Maxillofac Surg 66 2008 625 631
40. K. Zervas, E. Verrou, and Z. Teleioudis et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients Br J Haematol 134 2006 620 623
41. C.I. Ripamonti, M. Maniezzo, and T. Campa et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates: the experience of the National Cancer Institute of Milan Ann Oncol 20 2009 137 145
42. M.A. Dimopoulos, E. Kastritis, and C. Bamia et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid Ann Oncol 20 2009 117 120
43. S.L. Ruggiero, T.B. Dodson, and L.A. Assael et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update J Oral Maxillofac Surg 67 2009 2 12
44. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-9; discussion 1679.
45. Xgeva (denosumab) [package insert]. Thousand Oaks, CA, USA: Amgen Inc.; 2012.
46. G.A. Block, H.G. Bone, L. Fang, E. Lee, and D. Padhi A single-dose study of denosumab in patients with various degrees of renal impairment J Bone Miner Res 27 2012 1471 1479
47. C. Buonerba, M. Caraglia, and S. Malgieri et al. Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure? Expert Opin Biol Ther 13 2013 149 151
48. K. Olson, and C. Van Poznak Significance and impact of bisphosphonate-induced acute phase responses J Oncol Pharm Prac 13 2007 223 229
49. J.D. Wark, W. Bensen, and C. Recknor et al. Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg Osteoporos Int 23 2012 503 512
50. B.A. Lenart, D.G. Lorich, and J.M. Lane Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate N Engl J Med 358 2008 1304 1306